About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group is dedicated to paediatric research. We are interested in rare respiratory and endocrinological diseases, and also in common paediatric problems such as normal growth, asthma, neonatal pathology and imaging diagnosis, as well as minority diseases. Our goal is to transfer the findings of clinical and genetic studies to the widespread clinical practice and the general population, with the long-term objective of obtaining better diagnoses, implementing better therapeutic practices and improving the health of children.
Our group is part of CIBERER (Biomedical Research Networking Centre on Rare Diseases) (CIBERER U712) and European Reference Networks (ERN) for rare diseases ERN LUNG and Endo-ERN.
Bronchopulmonary dysplasia. Our current line in this subject is centered in studying the role of imaging in predicting the outcome of preterm babies with this chronic respiratory disease.
Omega-3 fatty acids supplementation and oxidative stress in preterm infants. The goal of this study is whether omega-3 fatty acids supplementation can decrease the incidence and severity of bronchopulmonary dysplasia and preterm retinopathy.
IP: Félix Castillo Salinas
Asthma and recurrent wheezing: Inflammatory markers. Insight into its pathogenesis and treatment.
Infant and children lung function: Reference values and clinical application.
IP: Antonio Moreno Galdó, Inés de Mir Messa
Our paediatric Cystic Fibrosis Unit is one of the most important in Spain regarding number of patients and clinical research. We are the only centre in Spain collaborating in the European Cystic Fibrosis Clinical Trial Network, and in the Cystic Fibrosis Core Network of ERN-Lung. Besides clinical investigation, we are working in translational lab projects in collaboration with the Genetic Medicine group to study the role of the eicosanoid pathway in the lung inflammation of this patients and, more importantly, to personalise the treatments for cystic fibrosis patients through the implementation of primary cultures of epithelial cells (bronchial, nasal) and organoids (rectal epithelium) and the study of transcripts and genomics by next generation sequencing in clinically diagnosed CF patients but with incomplete genomic characterization.
IP: Silvia Gartner Tizzano
1.1 Primary ciliary dyskinesia (PCD): We are a referral centre for diagnosis of PCD and we have established a clinical and research collaboration network with other national and international PCD diagnostic centres.
1.2 Paediatric interstitial lung diseases. We are leading the Spanish ISCIII registry for paediatric interstitial lung diseases and have started a project to characterize the incidence and the molecular basis of these rare diseases in Spain. We have international collaborations in this field (chILD EU registry and an E-rare 3 funded clinical trial).
1.3 Paediatric pulmonary hypertension. We have an active collaboration with the Spanish Registry of Paediatric Pulmonary Hypertension (REHIPED) and are developing an intense epidemiologic research in this area.
IP: Antonio Moreno Galdó
IP: Anna Gros Turpin Collaborators: Laura Gonzalez Garcia, ESTUDIO DE PREVALENCIA NACIONAL DE LESIONES CUTÁNEAS RELACIONADAS CON LA DEPENDENCIA EN POBLACIÓN NEONATAL, Raquel Rodríguez Gil, Lorena Tamborero Martin, Javier Garcia Fernandez, Pablo Buck Sainz Funding agency: Col·legi Oficial d'Infermers/es de Barcelona Funding: 5830 Reference: PR-730/2024 Duration: 01/01/2025 - 31/12/2026
IP: Maria Creu Regne Alegret Collaborators: Antonio Moreno Galdó, Mª Angeles Aceituno López, María Nieves Pelay Planes, Esperanza Zuriguel Pérez, Ester Navarro Correal Funding agency: Col·legi Oficial d'Infermers/es de Barcelona Funding: 6490 Reference: PR-613/2023 Duration: 01/01/2024 - 31/12/2026
IP: Nerea Maiz Elizaran Collaborators: Josefa Élida Vázquez Méndez, Marta Codina Solà, Ma Irene Valenzuela Palafoll, Silvia Arévalo Martínez, Carlota Rodó Rodríguez, Eulàlia Rovira Moreno, David Gómez Andrés, Amaia Lasa Aranzasti, Elena Moreno Perez Funding agency: Fundació La Marató de TV3 Funding: 197000 Reference: 202420-10 Duration: 20/02/2025 - 19/02/2028
IP: Inmaculada Fuentes Camps Collaborators: Antonio Moreno Galdó, Rafael Simó Canonge, Ariadna Martín Balcells, Mª Eulàlia Molinas Guilera, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez, Amaia Latasa Arrazubi, Joan Genescà Ferrer, Gemma Vona Giralt, Paula Isabel Roldan Caballero Funding agency: Instituto de Salud Carlos III Funding: 274920 Reference: PT23/00062 Duration: 01/01/2024 - 31/12/2026
The meeting, the most important event in the field worldwide, took place in Barcelona from 5 to 9 September and featured presentations of more than thirty VHIR studies.
The study, in which Vall d'Hebron participates, helps to understand the variability among patients with retinitis pigmentosa.
Es va reconèixer la tasca de més de 70 professionals dedicades a aquesta malaltia pulmonar, tant assistencial com de recerca.
